Copyright © 2021 InvestorPlace Media, LLC All rights reserved 1125 N Charles St, Baltimore, MD 21201

Second Sight (NASDAQ: EYES) shares soar significantly on Friday following US approval announcement Food and Drug Administration (FDA) for the Argus 2s Retinal Prosthetic System

Second Sight notes that the Argus 2s Retinal Prosthetic System is a revised version of the external hardware that is used alongside the Argus II implant.That hardware is glasses and a camera that are used to help people with retinitis pigmentosa (RP)

Plans are already in place for the Argus 2s retinal prosthesis system, according to Second Sight, with the company hoping to use it in the next generation of the Orion Visual Cortical Prosthesis System, a new treatment for RP that is currently being developed

Second Sight points out that the Argus 2s retinal prosthesis system offers several improvements over its predecessor, including better ergonomics and more powerful processing power.This better processor means video processing should see an increase in performance

Matthew Pfeffer, Acting CEO of Second Sight, said this about the news that boosted EYES stock on Friday

“We are very excited about this approval as it allows us to offer external hardware that we believe will improve comfort and aesthetics compared to the old Argus II system”

In addition to the news, the EYES share is also heavily traded today. To date, more than 297 million shares have changed hands. The daily average trading volume of the share is around 2 million shares

At the time of this writing, William White held positions (neither directly nor indirectly) in the securities referred to in this article

Financial market data from FinancialContent Services, Inc All rights reserved by Nasdaq
Citations were delayed by at least 15 minutes, all others by at least 20 minutes
Copyright ©
2021 InvestorPlace Media, LLC All rights reserved 1125 N Charles St, Baltimore, MD 21201

EYES) Share

World News – CA – EYES Share: The big FDA news whose shares go up on second glance

Source: https://investorplace.com/2021/03/eyes-stock-the-big-fda-news-that-has-second-sight-shares-soaring/